Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Cyclacel Pharmaceuticals Inc    

 SummaryChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2016 1,21 M
EBIT 2016 -15,0 M
Net income 2016 -11,9 M
Debt 2016 -
Yield 2016 -
Sales 2017 1,63 M
EBIT 2017 -26,0 M
Net income 2017 -22,7 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales2016 18,5x
Capi. / Sales2017 13,7x
Capitalization 22,3 M
More Financials
Company
Cyclacel Pharmaceuticals, Inc. is a diversified biopharmaceutical business focused in hematology and oncology based on a development pipeline of novel drug candidates.It is engaged in discovery, development and commercialization of novel, mechanism-targeted drugs to treat cancer and other serious... 
More about the company
Latest news on CYCLACEL PHARMACEUTICALS I
2016 CYCLACEL PHARMACEUTICALS, INC. (NASD : CYCC) Files An 8-K Departure of Directors..
2016 CYCLACEL PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form..
2016 CYCLACEL PHARMACEUTICALS, INC. (NASD : CYCC) Files An 8-K Other Events
2016 CYCLACEL PHARMACEUTICALS, INC. : Other Events (form 8-K)
2016 Cyclacel’s Novel PLK1 Inhibitor, CYC140, Demonstrates Therapeutic Poten..
2016 HERE’S WHY CYCLACEL PHARMACEUT : CYCC) Could Have A Rough December
2016 CYCLACEL PHARMACEUTICALS : CYCC) Files An 8-K Results of Operations and Financia..
2016 CYCLACEL PHARMACEUTICALS : Management's Discussion and Analysis of Financial Con..
2016 CYCLACEL PHARMACEUTICALS, INC. : Results of Operations and Financial Condition, ..
2016 Cyclacel Pharmaceuticals Reports 3rd Quarter 2016 Financial Results
More news
Sector news : Bio Therapeutic Drugs
01/13DJNOVARTIS : Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs
01/12 Investors in big pharma, biotech look to ride out Trump storm
01/12DJHot Stocks to Watch in the U.S. and Canada
01/10 Regeneron CEO says Amgen not putting patients first in patent dispute
01/09DJCELGENE : Anticipates Slowing Sales Growth for Main Drug Revlimid
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
2016 Midday Gainers / Losers
2016 Midday Gainers / Losers
2016 Cyclacel's lead product candidates show encouraging results in early-stage st..
2016 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
2016 Some Ideas For The Next Celator
Advertisement
Chart CYCLACEL PHARMACEUTICALS I
Duration : Period :
Cyclacel Pharmaceuticals I Technical Analysis Chart | US23254L3069 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price -
Spread / Average Target -100%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Spiro Rombotis President, Chief Executive Officer & Director
David C. U'Prichard Chairman
Paul McBarron COO, CFO, Secretary, Director & Executive VP
David Glover Chief Scientist
John Michael Middlecott Banham Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CYCLACEL PHARMACEUTICA..7.17%23
AMGEN, INC.5.79%114 415
GILEAD SCIENCES, INC.-0.84%94 290
CELGENE CORPORATION-2.67%88 079
REGENERON PHARMACEUTIC..-1.23%38 329
ACTELION LTD4.58%24 308
More Results